Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about HitGen and Pfizer Enter Research Collaboration and License Agreement to Build and Screen Novel DNA-Encoded Libraries
HitGen Ltd. is pleased to announce that the company has entered into a multi-year research collaboration and license agreement with Pfizer Inc. (NYSE: PFE) to build and screen novel DNA-encoded libraries (DELs) in order to potentially discover unique small molecule leads to be used in drug development. Through the collaboration, HitGen and Pfizer scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for Pfizer’s drug discovery efforts. In addition, HitGen will screen their own DELs, consisting of billions of compounds, against a selected number of Pfizer’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to Pfizer for further research and development. Pfizer will fund the research at HitGen.
- Read more about NPPA release Guideline and Standard Operating Procedure for disposal of review cases
National drug price regulator the National Pharmaceutical Pricing Authority (NPPA) has issued Guideline and Standard Operating Procedure for disposal of such review cases.
- Read more about Government set up Panel to curb prices of key drugs
Health care spending has increased as the burden of critical illnesses such as cancer, diabetes and hypertension is constantly increasing, requiring patients to continue taking medications throughout their lives.
- Read more about FSSAI get online access to 70,000 food standards in more than 170 countries
Food Safety and Standard Authority of India (FSSAI) a conclusion without agreement with the US company Decernis, which helps it access the database of more than 70,000 standards for food additives, food standards, Food and contaminants from more than 170 countries, said the organization in a statement.
- Read more about Government taking policy initiatives to discourage import of bulk drugs
The government is taking various policy initiatives, including the withdrawal of tariff exemption, to discourage imports of bulk drugs and active pharmaceutical ingredients (APIs) into the country.
- Read more about Hallstar’s breakthrough Anti-Aging Chemistry, Micah, Takes Silver at the Global in-cosmeticsInnovation Ingredient awards
Hallstar, a specialty chemical company based in Chicago, has been awarded the 2017 Global in-cosmetics^® Innovation Silver Prize for its revolutionary new anti-aging ingredient, Micah. Winners were announced at the in-cosmetics^® conference in London on April 4th. The awards are given to honor the development of a novel active or functional ingredient combining innovative science and product features in a way that demonstrates substantial benefits to manufacturers and end-users.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
Novartis announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing conditions including regulatory approvals. The financial and other terms of this transaction are not disclosed.
- Read more about FDA approves two hepatitis C drugs for pediatric patients
The U.S. Food and Drug Administration approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.
- Read more about Parliament approve bill to ensure equal rights to people affected by HIV
Parliament passed the bill to ensure equal rights for people living with HIV and AIDS in treatment, employment and admissions to educational institutions.
- Read more about Intellia Therapeutics announces European Patent office’s decision to Grant CRISPR/Cas9 Genome Editing Technology Patent
Intellia Therapeutics a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, announced that the European Patent Office (EPO) has decided to grant a patent broadly covering the CRISPR/Cas9 genome editing technology. The patent includes claims covering compositions of the widely adopted CRISPR single guide RNA technology for use in any non-cellular and cellular setting, including eukaryotic cells such as human or mammalian cells, as well as for use in human therapeutics.